Regular Delivery service available
Trusted by trustpilot!
FREE DELIVERY available from £29

Relaquine Oral Gel for Horses

  • 10ml Syringe £19.49

Relaquine Gel is a sedative given by mouth to horses. It produces mild to moderate sedation but no analgesic effect, so is not suitable on its own for painful procedures. The effects wear off after about 6 hours, but this varies considerably with the dose given and in individual horses.

Qualitative and quantitative composition

1 ml contains: Active substance:

Acepromazine 35.00 mg (as acepromazine maleate 47.50 mg)


Methyl parahydroxybenzoate 0.65 mg

Propyl parahydroxybenzoate 0.35 mg

For a full list of excipients, see Excipients.

Pharmaceutical form

Oral gel. Clear yellow gel for oral administration.

Clinical particulars

Target species


Indications for use

For sedation of horses.


Do not use in cases of post-traumatic shock or hypovolaemia.

Do not use in animals in a state of severe emotional excitation.

Do not use in animals with epilepsy.

Do not use in pregnant or lactating mares.

Do not use in animals with heart failure.

Do not use in animals with haematological disorders/coagulopathies.

Do not use in animals suffering from hypothermia.

Do not use in the case of known hypersensitivity to the active substance or any of the excipients of the product.

Special warnings for each target species

Sedation lasts for approximately six hours, although the actual time and depth of sedation are very dependent on the status of the individual animal.

Increasing the dosage above that recommended results in prolonged action and side effects but no greater sedation.

Special precautions for use in animals

In stallions, the lowest dose range is indicated to minimise prolapse of the penis.

The product should be used with caution and with reduced dosage in the case of cardiac or hepatic disease or in debilitated, hypovolemic or anaemic animals.

Acepromazine has negligible analgesic effects. Painful activities should be avoided when handling tranquilised animals.

Tranquilised horses should be kept in a calm place and sensorial stimuli should be avoided as far as possible.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands and exposed skin thoroughly after use. Persons with sensitive skin or in continuous contact with the product are advised to wear impermeable gloves.

Avoid contact with eyes. If accidental eye contact occurs, flush gently with running water for 15 minutes and seek medical advice if any irritation persists.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse reactions

Since acepromazine decreases sympathetic nervous system tone, a transient drop in blood pressure may occur after administration.

Inhibition of temperature regulation.

The following reversible changes are possible in the haemogram:

- Transient decrease in erythrocyte count and haemoglobin concentration;

- Transient decrease in thrombocyte and leukocyte counts.

Because it increases prolactin secretion, the administration of acepromazine may lead to disturbances in fertility.

Penile prolapse may occur due to the relaxation of the retractor penis muscles. Retraction of the penis should be visible within two to three hours. If this does not take place, it is advised to contact a veterinary surgeon. Lack of retraction is of particular concern in breeding stallions.

Acepromazine has caused paraphimosis sometimes in sequel to priaprism.

In rare cases paradoxical excitation reactions can develop.

Contradictory clinical signs of aggressiveness and generalised CNS stimulation may occur.

Prolapse of the nictitating membrane has also been cited as a possible adverse effect in horses.

Use during pregnancy and lactation

Acepromazine should not be used in pregnant or lactating mares.

Acepromazine has the potential to induce hypotension in newborns when administered as a pre-medication for caesarean section in the mare.

Please see also Adverse reactions section in relation to disturbances in fertility.


Acepromazine potentiates the action of centrally depressant drugs.

The simultaneous use of organic phosphate esters increases the toxicity of acepromazine.

Since acepromazine decreases sympathetic nervous system tone, it should not be given at the same time as blood pressure reducing drugs.

Antacids may cause a decrease in the gastrointestinal absorption of acepromazine after oral administration.

Opiates may enhance the hypotensive effects of acepromazine.

Amounts to be administered and administration route

Administration route: For oral administration. Place the syringe in the animal's mouth and expel the required dose into the cheek pouch. The gel may also be mixed with food.

Amounts to be administered: Moderate sedation: 0.15 mg acepromazine per kg body weight.

Dosage guidelines:

Body weight (kg)







Dose (ml)







The above dosage information is provided as a guideline. The dose may be varied to administer between 0.5 and 1.5 times the above recommendation depending on the level of sedation required, i.e. for mild sedation, administer half the recommended dose and for deeper sedation, administer 1½ times the recommended dose.

Because of the difficulty in ensuring the accurate delivery of small doses, the product should only be used in horses of less than 200 kg body weight in accordance with a benefit/risk assessment by the responsible veterinarian.


Overdosage results in an earlier onset of the sedative symptoms and in a prolonged effect.

Toxic effects are ataxia, hypotension, hypothermia and central nervous system (extrapyramidal) effects.

Noradrenaline, but not adrenaline, can be used to counteract the cardiovascular effects.

Withdrawal period

Do not use in horses intended for human consumption.

Pharmacological particulars

Pharmacotherapeutic group: Nervous system.

ATC Vet code: QN05AA04

Pharmacodynamic properties

Acepromazine is a phenothiazine derivative. This group of molecules belongs to the neuroleptics: they depress the central nervous system and exert associated effects on the autonomic system. These effects are due to their interference with different neurotransmitter receptors (dopaminergic, adrenergic) and to their interference with hypothalamic performance. The sedative activity starts within 15 to 30 minutes of treatment and lasts for 6-7 hours.

The desired effects observed after treatment with acepromazine include a general tranquilising effect, anti-emetic effect and a slight anti-histaminic effect. There is no analgesic action. The neuroleptic effects are variable between individual animals.

Pharmacokinetic properties

Acepromazine is partly absorbed from the gastrointestinal tract. Plasma protein binding is high and it is extensively distributed throughout the body tissues. Plasma levels are usually low. Acepromazine is highly metabolised, with the urine as the main route of excretion.

Pharmaceutical particulars


Methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate, sodium acetate trihydrate, sodium cyclamate (E952), hydroxyethylcellulose, glycerol (E422), purified water.


Simultaneous administration, or administration to horses recently treated with organophosphates, should be avoided, since these molecules enhance the toxic effects of acepromazine. Simultaneous treatment with blood pressure lowering products should be avoided.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the container: 28 days.

Special precautions for storage

Do not store above 25°C. Protect from frost. Protect from light. When the container is broached (opened) for the first time, use within 28 days. After use, replace cap on syringe. Keep the broached syringe in the original carton and store in a dry place. Keep out of the reach and sight of children.

Immediate packaging

Container: White, high-density polyethylene syringe barrel. White, low-density polyethylene syringe plunger.

Closure: White, high-density polyethylene, push-fit cap.

Fill volume: 10 ml.

Dosing device: The product is presented in an oral dosing syringe which is graduated at 1 ml intervals.


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing authorisation holder (if different from distributor)

Floris Veterinaire Produkten BV, Kempenlandstraat 33, 5262 GK Vught, The Netherlands.

Marketing authorisation number

Vm 36057/4001.

Date of the first authorisation or date of renewal


Date of revision of the text

May 2013

Any other information

For animal treatment only. To be supplied only on veterinary prescription.

Legal category


GTIN (Global Trade Item No)

Relaquine 35 mg/ml Oral Gel for Horses 10 ml:


Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm
  • Email:

All prices include VAT where applicable.

Reviews of Relaquine Oral Gel for Horses

Read our customers' reviews of Relaquine Oral Gel for Horses

Questions & Answers for Relaquine Oral Gel for Horses

There are currently no questions for Relaquine Oral Gel for Horses - be the first to ask one!

Ask A Question